Cargando…
Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vasc...
Autores principales: | Chang, Che-Yi, Wang, Ming-Chen, Miyagawa, Takuya, Chen, Zhi-Yu, Lin, Feng-Huei, Chen, Ko-Hua, Liu, Guei-Sheung, Tseng, Ching-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221810/ https://www.ncbi.nlm.nih.gov/pubmed/28115846 http://dx.doi.org/10.2147/IJN.S114754 |
Ejemplares similares
-
Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization via Inhibition of VEGF Production
por: Miyagawa, Takuya, et al.
Publicado: (2020) -
Development of Kaempferol-Loaded Gelatin Nanoparticles for the Treatment of Corneal Neovascularization in Mice
por: Chuang, Yu-Lun, et al.
Publicado: (2019) -
Epigalloccatechin-3-gallate Inhibits Ocular Neovascularization and Vascular Permeability in Human Retinal Pigment Epithelial and Human Retinal Microvascular Endothelial Cells via Suppression of MMP-9 and VEGF Activation
por: Lee, Hak Sung, et al.
Publicado: (2014) -
Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides
por: Wu, Meijia, et al.
Publicado: (2018) -
Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
por: Wang, Chen, et al.
Publicado: (2022)